Evidence map›Paper›PMID 25809442›Full record

ReviewProteomics2015

Proteomic approaches to analyzing hepatitis C virus biology.

Florian Douam, Alexander Ploss

Open access · greenAbstract readReview
In one paragraph

Review in Proteomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Florian DouamDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Alexander PlossDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA.
Princeton University · US

Funding

Genetic Viral and Host Adaptations to Breach Species Barriers of HCVR01AI107301 · NIAID · PRINCETON UNIVERSITY · PI Thomas Pietschmann, Alexander Ploss · 2013 to 2026
$6.0M
Understanding human neutralizing antibodies to hepatitis C virusR01AI079031 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2008 to 2017
$4.6M
Dissecting virus neutralizing determinants to guide HCV vaccine developmentR01AI106005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2014 to 2017
$1.5M
Dissecting virus neutralizing determinants to guide HCV vaccine developmentR56AI106005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2013 to 2013
$793k
Impact of species-specific host responses on restriction of hepatotropic virusesR21AI117213 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER, SCHWARTZ, ROBERT E · 2015 to 2016
$471k
Transmitted/Founder HCV clones as targets for treatment and eradication.R21AI106000 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PLOSS, ALEXANDER, RICE, CHARLES M · 2013 to 2014
$452k
NIAID NIH HHS 1 R01 AI107301-01NIAID NIH HHS 1 R56 AI106005-01NIAID NIH HHS 2 R01 AI079031-05A1NIAID NIH HHS R01 AI079031NIAID NIH HHS R01 AI106005NIAID NIH HHS R01 AI107301NIAID NIH HHS R21 AI106000NIAID NIH HHS R21 AI117213NIAID NIH HHS R56 AI106005
6 · The paper itself

Abstract

Hepatitis C virus (HCV) is a major cause of liver disease worldwide. Acute infection often progresses to chronicity resulting frequently in fibrosis, cirrhosis, and in rare cases, in the development of hepatocellular carcinoma. Although HCV has proven to be an arduous object of research and has raised important technical challenges, several experimental models have been developed all over the last two decades in order to improve our understanding of the virus life cycle, pathogenesis and virus-host interactions. The recent development of direct acting-agents, leading to considerable progress in treatment of patients, represents the direct outcomes of these achievements. Proteomic approaches have been of critical help to shed light on several aspect of the HCV biology such as virion composition, viral replication, and virus assembly and to unveil diagnostic or prognostic markers of HCV-induced liver disease. Here, we review how proteomic approaches have led to improve our understanding of HCV life cycle and liver disease, thus highlighting the relevance of these approaches for studying the complex interactions between other challenging human viral pathogens and their host.

Indexed as

HepacivirusHepatitis CHumansProteomicsHepatitis C virusMicrobiologyMSVirus-host interactionsVirus life cycle

Identifiers

PMID25809442
PMCPMC4559851
OpenAlexW2069772801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.